Its product, MyoCell, improves cardiac function in chronic heart failure patients by populating scar tissue with autologous muscle cells. The company specializes in developing proprietary stem cell therapies, regenerative solutions, physician training, veterinary applications, and stem cell banking. It has completed more clinical treatments than any other regenerative care provider and has trained over 700 physicians.